IL6R was also the target of a drug that we identified and has been evaluated in a clinical trial for its efficacy in primary Sjögren’s Syndrome (pSS) patients (NCT01782235) (Table 2) [38]. This evidence concerns the gene IL6R and peeling skin syndrome.